An update from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On September 16, 2025, Dr. Reddy’s Laboratories announced the launch of ...

The rollout follows Dr. Reddy’s exclusive licensing deal with South Korea’s HK inno.N Corp. in 2022 to commercialize ...

Dr. Reddy’s Laboratories launches Tegoprazan for acid-related gastrointestinal diseases in India, enhancing patient access to ...

Dr Reddy’s Laboratories launched Tegoprazan in India, a next-gen acid blocker for acid peptic diseases. With a significant portion of Indians affected by such conditions, this launch follows a ...

Tegoprazan is a next-generation potassium-competitive acid blocker. It is indicated for the treatment of acid peptic diseases ...

Dr Reddy's unveils novel molecule ‘Tegoprazan’ in India under brand name PCAB for acid-related GI diseases: Our Bureau, Bengaluru Wednesday, September 17, 2025, 12:20 Hrs [IST ...

In a major setback for Swiss drugmaker Novartis, the Indian Patent Office (IPO) has cancelled the patent for its heart ...

Beta-blocker therapy reduced the risk of death or major adverse cardiovascular events by 15% in patients with MI and a LVEF ...

Dr Reddy's has launched Tegoprazan, a next-generation acid blocker, in India to treat GERD, NERD, and gastric ulcers, ...